Cybin (HELP) Change in Receivables (2020 - 2026)
Cybin's (HELP) quarterly Change in Receivables came in at -$262000.0 in Q1 2026, down 24.48% YoY from -$346946.4 in Q1 2025, and down 745.16% on a QoQ basis from -$31000.0 in Q4 2025.
Cybin (HELP) Change in Receivables (2020 - 2026) Analysis & Trends
Cybin (HELP) has 7 years of Change in Receivables data on file, last reported at -$262000.0 in Q1 2026.
- Quarterly Change in Receivables fell 24.48% year-over-year to -$262000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$934000.0 (up 8.46% YoY) and the FY2026 annual result came in at -$934000.0, down 18.23% from the prior year.
- Change in Receivables retreated to -$262000.0 in Q1 2026, from -$31000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $380787.3 in Q2 2022 to a low of -$649485.3 in Q3 2024.
- A 5-year average of -$176312.9 and a median of -$163264.9 in 2024 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables soared 97.13% — and 2023, when it sank 197.65%.
- Tracing HELP's Change in Receivables over 5 years: stood at $178282.1 in 2022, then slumped by 197.65% to -$174084.9 in 2023, then surged by 67.93% to -$55836.2 in 2024, then jumped by 44.48% to -$31000.0 in 2025, then sank by 745.16% to -$262000.0 in 2026.
- The last three Change in Receivables figures came in at -$262000.0 (Q1 2026), -$31000.0 (Q4 2025), and -$630000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | -262,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -262,000.00 |
| Mar 31, 2026 | -262,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Sep 30, 2025 | -630,000.00 |
| Sep 30, 2025 | -630,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Mar 31, 2025 | -210,468.78 |
| Mar 31, 2025 | -210,468.78 |
| Dec 31, 2024 | -55,836.23 |
| Dec 31, 2024 | -55,836.23 |
| Sep 30, 2024 | -649,485.32 |
| Sep 30, 2024 | -649,485.32 |
| Jun 30, 2024 | -104,553.10 |
| Jun 30, 2024 | -104,553.10 |
| Mar 31, 2024 | -163,264.91 |
| Mar 31, 2024 | -163,264.91 |
| Dec 31, 2023 | -174,084.92 |
| Dec 31, 2023 | -174,084.92 |